Development and Characterization of β-Cyclodextrin Inclusion Complexes With Enzalutamide for Easing Administration and Efficacy of the Drug in CRPC

Author

Meghana Kolli, The University of Texas Rio Grande Valley

Date of Award

7-1-2024

Document Type

Thesis

Degree Name

Master of Science (MS)

Department

Biochemistry and Molecular Biology

First Advisor

Murali M. Yallapu

Second Advisor

Subhash C. Chauhan

Third Advisor

Nirakar Sahoo

Abstract

Prostate cancer (PC) is prevalent among men in the US, often leading to castration-resistant prostate cancer (CRPC) with therapy. This is marked by androgen receptor (AR) overexpression, resistance, mutations, and splice variants. Enzalutamide (ENZ), a nonsteroidal antiandrogen, surpasses first-gen AR inhibitors like Bicalutamide. It's the go-to drug for CRPC. We explore ENZ for self-assembly complex formation, crucial for CRPC treatment. Using the solvent evaporation method, we developed β-cyclodextrin and ENZ self-assembly complexes (β-CD-ENZ). β-CD acts as both agent and solubilizer, FDA-approved and safe. Efficacy was tested on PC cell lines (C4-2B) and (22Rv1), including 3D cultures for cytotoxicity and a Caco-2 permeability assay. H-β-CD fibers with the drug were compressed into tablets for easy administration. Our findings indicate β-CD-ENZ complex fibers outperform free ENZ, promising for CRPC treatment.

Comments

Copyright 2024 Meghana Kolli. https://proquest.com/docview/3115242616

Recommended Citation

Kolli, Meghana, "Development and Characterization of β-Cyclodextrin Inclusion Complexes With Enzalutamide for Easing Administration and Efficacy of the Drug in CRPC" (2024). Theses and Dissertations. 1542.
https://scholarworks.utrgv.edu/etd/1542